trial · primary record
Nivolumab
Glioblastoma (GBM)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 34 |
| Primary completion | 2028-03 |
| Primary endpoint | Incidence of adverse events |
| Registry ID | NCT06896110 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:43.724Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06896110
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.